Literature DB >> 10671355

Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin).

S A McNeil1, N M Clark, P H Chandrasekar, C A Kauffman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10671355     DOI： 10.1086/313669

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

Review 1.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C F Dailey; C L Dileto-Fang; L V Buchanan; M P Oramas-Shirey; D H Batts; C W Ford; J K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.

Authors:  I Raad; R Hachem; H Hanna; E Girgawy; K Rolston; E Whimbey; R Husni; G Bodey
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

4.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

5.  Issues in the Management of Endocarditis Caused by Resistant Gram-positive Organisms.

Authors:  Martin E. Stryjewski; Vivian H. Chu; Christopher H. Cabell; Vance G. Fowler
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.